Skip to main content
Fig. 4 | BMC Cancer

Fig. 4

From: Neoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for ER-positive, HER2-negative breast cancer: a randomized pilot trial

Fig. 4

Associations between changes of blood immune cell subpopulations and therapeutic response after neoadjuvant therapy. a. Changes of percentage of B cells from responders (PR) or non-responders (SD/PD) after neoadjuvant therapy were analyzed. Non-responders (SD/PD) to neoadjuvant therapy had a greater decrease in blood B cell percentages compared to responders (PR) after neoadjuvant therapy. b. Changes of numbers of circulating tumor-specific CTLs (IFN-γ+ CTLs) from responders (PR) or non-responders (SD/PD) after NET were analyzed. Responders had a greater increase in the number of circulating tumor-specific CTLs compared to non-responders after NET. Statistical analysis was performed by Chi-square test and P < 0.05 was considered statistically significant

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us